184 related articles for article (PubMed ID: 22185667)
1. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.
Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR
Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667
[TBL] [Abstract][Full Text] [Related]
2. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
3. Beta-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy.
Devalapally H; Navath RS; Yenamandra V; Akkinepally RR; Devarakonda RK
Arch Pharm Res; 2007 Jun; 30(6):723-32. PubMed ID: 17679550
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
6. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2008 Jul; 18(14):4059-63. PubMed ID: 18556201
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
8. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
9. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
Günther M; Waxman DJ; Wagner E; Ogris M
Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells.
Roth T; Tang W; Eisenbrand G
Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents.
Steinberg G; Borch RF
J Med Chem; 2001 Jan; 44(1):69-73. PubMed ID: 11141089
[TBL] [Abstract][Full Text] [Related]
13. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
14. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
15. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
Jain M; Kwon CH
J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Chen L; Yu LJ; Waxman DJ
Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
[TBL] [Abstract][Full Text] [Related]
18. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs.
Pedersen PJ; Christensen MS; Ruysschaert T; Linderoth L; Andresen TL; Melander F; Mouritsen OG; Madsen R; Clausen MH
J Med Chem; 2009 May; 52(10):3408-15. PubMed ID: 19402667
[TBL] [Abstract][Full Text] [Related]
20. Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs.
Cytarska J; Misiura K; Filip-Psurska B; Wietrzyk J
Acta Pol Pharm; 2013; 70(3):481-7. PubMed ID: 23757939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]